Free Trial

Tango Therapeutics (TNGX) News Today

Tango Therapeutics logo
$1.94 -0.11 (-5.37%)
Closing price 04:00 PM Eastern
Extended Trading
$1.96 +0.02 (+0.77%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TNGX Latest News

Tango Therapeutics, Inc. stock logo
Woodline Partners LP Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)
Woodline Partners LP purchased a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 394,397 shares of the company's stock, valued at approximately $1,219,000. Woodline Partners LP owned 0.
Tango Therapeutics, Inc. stock logo
517,426 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Jacobs Levy Equity Management Inc.
Jacobs Levy Equity Management Inc. bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 517,426 shares of the company's stock, valued at approx
Tango Therapeutics, Inc. stock logo
Q2 EPS Estimate for Tango Therapeutics Increased by Analyst
Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities research analysts at Leerink Partnrs raised their Q2 2025 earnings per share estimates for Tango Therapeutics in a report issued on Monday, May 12th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings p
Tango Therapeutics, Inc. stock logo
Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)
Dimensional Fund Advisors LP lifted its position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 83.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 662,776 shares of the company's stock after pu
Tango Therapeutics, Inc. stock logo
Orbimed Advisors LLC Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)
Orbimed Advisors LLC bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 550,000 shares of the company's stock, valued at
Tango Therapeutics, Inc. stock logo
Tango Therapeutics (NASDAQ:TNGX) Posts Earnings Results, Misses Estimates By $0.02 EPS
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%.
Tango Therapeutics, Inc. stock logo
4,000,000 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Bought by Farallon Capital Management LLC
Farallon Capital Management LLC bought a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,000,000 shares of the company's stock, valued at approximat
Tango Therapeutics, Inc. stock logo
Balyasny Asset Management L.P. Has $10.13 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)
Balyasny Asset Management L.P. raised its position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 22.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,279,196 shares
Tango Therapeutics, Inc. stock logo
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Buy" by Analysts
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has been assigned an average rating of "Buy" from the seven research firms that are currently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price obje
Tango Therapeutics, Inc. stock logo
Tango Therapeutics (TNGX) to Release Quarterly Earnings on Monday
Tango Therapeutics (NASDAQ:TNGX) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-tango-therapeutics-inc-stock/)
Tango Therapeutics, Inc. stock logo
Boxer Capital Management LLC Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)
Boxer Capital Management LLC purchased a new position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,380,999 shares of the company's stock,
Tango Therapeutics, Inc. stock logo
Susquehanna Fundamental Investments LLC Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)
Susquehanna Fundamental Investments LLC acquired a new position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 347,271 shares of the compa
Tango Therapeutics, Inc. stock logo
TCG Crossover Management LLC Invests $33.17 Million in Tango Therapeutics, Inc. (NASDAQ:TNGX)
TCG Crossover Management LLC bought a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,736,000 shares of t
Tango Therapeutics, Inc. stock logo
Nantahala Capital Management LLC Invests $8.67 Million in Tango Therapeutics, Inc. (NASDAQ:TNGX)
Nantahala Capital Management LLC acquired a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 2,804,410 shares of the company's stock, valued at approximately $8,666,000. Na
Tango Therapeutics, Inc. stock logo
T. Rowe Price Investment Management Inc. Trims Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)
T. Rowe Price Investment Management Inc. cut its holdings in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 33.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,345,551 shares of the company's stock after selling 1,677,595 shar
Tango Therapeutics, Inc. stock logo
Blue Owl Capital Holdings LP Acquires New Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)
Blue Owl Capital Holdings LP bought a new position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,732,152 shares of the company
Tango Therapeutics, Inc. stock logo
Trv Gp Vi LLC Acquires New Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)
Trv Gp Vi LLC bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 194,174 shares of the company's s
Tango Therapeutics, Inc. stock logo
Gilead Sciences Inc. Acquires Shares of 4,854,443 Tango Therapeutics, Inc. (NASDAQ:TNGX)
Gilead Sciences Inc. bought a new position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,854,443 shares of the company's stock, valued at approximately
Tango Therapeutics, Inc. stock logo
HC Wainwright Brokers Reduce Earnings Estimates for TNGX
Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Tango Therapeutics in a research report issued on Monday, April 14th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.35) per share for the
Tango Therapeutics, Inc. stock logo
Q1 Earnings Forecast for TNGX Issued By HC Wainwright
Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Monday, April 14th. HC Wainwright analyst R. Burns forecasts that the company
Tango Therapeutics, Inc. stock logo
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Buy" from Analysts
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has been given an average recommendation of "Buy" by the seven research firms that are covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month price target amon
Tango Therapeutics, Inc. stock logo
HC Wainwright Reiterates Buy Rating for Tango Therapeutics (NASDAQ:TNGX)
HC Wainwright reissued a "buy" rating and issued a $13.00 price objective on shares of Tango Therapeutics in a report on Monday.
Barbara Weber, M.D., Elected to ITM Supervisory Board
Tango Therapeutics, Inc. stock logo
Schroder Investment Management Group Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)
Schroder Investment Management Group bought a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 655,158 shares of the company's stock, valued at a
Tango Therapeutics, Inc. stock logo
Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Expands By 29.4%
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 9,110,000 shares, an increase of 29.4% from the February 28th total of 7,040,000 shares. Approximately 15.4% of the shares of the company are sold short. Based on an average daily volume of 873,500 shares, the days-to-cover ratio is presently 10.4 days.
Barclays Sticks to Its Buy Rating for Tango Therapeutics (TNGX)
Tango Therapeutics, Inc. stock logo
Tango Therapeutics, Inc. (NASDAQ:TNGX) Sees Large Growth in Short Interest
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 7,040,000 shares, a growth of 18.5% from the February 13th total of 5,940,000 shares. Approximately 11.9% of the shares of the stock are sold short. Based on an average daily volume of 967,300 shares, the short-interest ratio is currently 7.3 days.
Tango Therapeutics, Inc. stock logo
Cantor Fitzgerald Has Weak Estimate for TNGX FY2025 Earnings
Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Monday, March 10th. Cantor Fitzgerald analyst E. Schmid
Tango Therapeutics, Inc. stock logo
Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday
Tango Therapeutics (NASDAQ:TNGX) will be releasing earnings before the market opens on Monday, March 17, Financial Modeling Prep reports.
Tango Therapeutics (TNGX) Receives a Buy from Barclays
Tango Therapeutics, Inc. stock logo
Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%.
Tango Therapeutics sees cash runway into 3Q26
Tango Therapeutics reports Q4 EPS (35c), consensus (34c)
Tango Therapeutics, Inc. stock logo
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Buy" from Brokerages
Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have been given an average recommendation of "Buy" by the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The averag
Tango Therapeutics, Inc. stock logo
Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Decreases By 22.5%
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 5,440,000 shares, a decrease of 22.5% from the January 15th total of 7,020,000 shares. Based on an average daily trading volume, of 1,720,000 shares, the days-to-cover ratio is presently 3.2 days. Currently, 11.0% of the shares of the company are sold short.
Get Tango Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter.

TNGX Media Mentions By Week

TNGX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TNGX
News Sentiment

0.44

1.03

Average
Medical
News Sentiment

TNGX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TNGX Articles
This Week

5

3

TNGX Articles
Average Week

Get Tango Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:TNGX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners